Abo Bibliothek: Guest
Critical Reviews™ in Therapeutic Drug Carrier Systems

Erscheint 6 Ausgaben pro Jahr

ISSN Druckformat: 0743-4863

ISSN Online: 2162-660X

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.7 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 3.6 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.8 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00023 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.39 SJR: 0.42 SNIP: 0.89 CiteScore™:: 5.5 H-Index: 79

Indexed in

Delivery of Biotherapeutics by Inhalation Aerosol

Volumen 12, Ausgabe 2-3, 1995, pp. 151-231
DOI: 10.1615/CritRevTherDrugCarrierSyst.v12.i2-3.20
Get accessGet access

ABSTRAKT

The role of inhalation therapy is adapting to changes brought on by advances in several related disciplines. These range from device technology to the molecular and cell biology of the lungs. Acceptable bioavailability and efficacy have been achieved via the oral route for most traditional pharmaceuticals. Unfortunately, injection is the normal mode of delivery with biotherapeutic agents and alternative delivery approaches are needed. Many preclinical and clinical studies with inhaled proteins, peptides, and DNA have been completed and demonstrate that efficacy can be achieved within the lungs and systemically. Despite the promising results, the development of inhaled biotherapeutics is beset with unique problems that require an integrated and rational approach to development. Aqueous protein formulations are often not stable to aerosolization, while stability of powder formulations can be difficult to evaluate in the solid state. Inhaler efficiency and reproducibility are unacceptable with existing devices and, although improvements in technology have brightened the outlook, new devices are not yet available and remain untried with most biotherapeutics. Once delivered to the lungs, these molecules are also subjected to a variety of efficient clearance mechanisms that can significantly reduce the probability of them being effective. Despite these problems, the number of potential drugs being tested via inhalation continues to increase, suggesting some promise of future success. This review discusses the above issues and highlights a variety of biotherapeutics that have been administered as inhalation aerosols.

REFERENZIERT VON
  1. Tandel Hemal, Florence Kiruba, Misra Ambikanandan, Protein and Peptide Delivery through Respiratory Pathway, in Challenges in Delivery of Therapeutic Genomics and Proteomics, 2011. Crossref

  2. Zhao Ying-Zheng, Li Xing, Lu Cui-Tao, Xu Yan-Yan, Lv Hai-Feng, Dai Dan-Dan, Zhang Lu, Sun Chang-Zheng, Yang Wei, Li Xiao-Kun, Zhao Ya-Ping, Fu Hong-Xing, Cai Lu, Lin Min, Chen Li-Juan, Zhang Ming, Experiment on the feasibility of using modified gelatin nanoparticles as insulin pulmonary administration system for diabetes therapy, Acta Diabetologica, 49, 4, 2012. Crossref

  3. Ahmad Khanbeigi Raha, Kumar Abhinav, Sadouki Fethi, Lorenz Chris, Forbes Ben, Dailey Lea Ann, Collins Helen, The delivered dose: Applying particokinetics to in vitro investigations of nanoparticle internalization by macrophages, Journal of Controlled Release, 162, 2, 2012. Crossref

  4. Lyubimov Alexander V., Dosage Formulation, in Pharmaceutical Sciences Encyclopedia, 2010. Crossref

  5. Marek Stephen, Smyth Hugh, Garcia-Contreras Lucila, Cooney Daniel, Garmise Robert, Jones Latarsha, Hickey Anthony, Medical and Pharmaceutical Aerosols, in Aerosols Handbook, 2012. Crossref

  6. Fischer A, Stegemann J, Scheuch G, Siekmeier R, Novel devices for individualized controlled inhalation can optimize aerosol therapy in efficacy, patient care and power of clinical trials, European Journal of Medical Research, 14, Suppl 4, 2009. Crossref

  7. TAZAWA Ryushi, NAKATA Koh, INOUE Yoshikazu, NUKIWA Toshihiro, Granulocyte-macrophage colony-stimulating factor inhalation therapy for patients with idiopathic pulmonary alveolar proteinosis: a pilot study; and long-term treatment with aerosolized granulocyte-macrophage colony-stimulating factor: a case report, Respirology, 11, s1, 2006. Crossref

  8. Hoe Susan, Boraey Mohammed A., Ivey James W., Finlay Warren H., Vehring Reinhard, Manufacturing and Device Options for the Delivery of Biotherapeutics, Journal of Aerosol Medicine and Pulmonary Drug Delivery, 27, 5, 2014. Crossref

  9. Patel Gaurang, Chougule Mahavir, Singh Mandip, Misra Ambikanandan, Nanoliposomal Dry Powder Formulations, in Liposomes, Part F, 464, 2009. Crossref

  10. Nanoparticles in Drug Delivery Systems, in Nanomedicine in Drug Delivery, 2013. Crossref

  11. Samra Zahoor Qadir, Ahmad Snober, Javeid Mehwish, Dar Nadia, Aslam Muhammad Shahbaz, Gull Iram, Ahmad Mubashar Mustaneer, ANTICANCER MEDICINES (DOXORUBICIN AND METHOTREXATE) CONJUGATED WITH MAGNETIC NANOPARTICLES FOR TARGETING DRUG DELIVERY THROUGH IRON, Preparative Biochemistry and Biotechnology, 43, 8, 2013. Crossref

  12. Charman William N., Chan Hak-Kim, Finnin Barrie C., Charman Susan A., Drug delivery: A key factor in realising the full therapeutic potential of drugs, Drug Development Research, 46, 3-4, 1999. Crossref

  13. Nahar Kamrun, Gupta Nilesh, Gauvin Robert, Absar Shahriar, Patel Brijeshkumar, Gupta Vivek, Khademhosseini Ali, Ahsan Fakhrul, In vitro, in vivo and ex vivo models for studying particle deposition and drug absorption of inhaled pharmaceuticals, European Journal of Pharmaceutical Sciences, 49, 5, 2013. Crossref

  14. Traini Daniela, Inhalation Drug Delivery, in Inhalation Drug Delivery, 2013. Crossref

  15. Young Paul M., Crapper John, Philips Gary, Sharma Ketan, Chan Hak-Kim, Traini Daniela, Overcoming Dose Limitations Using the Orbital® Multi-Breath Dry Powder Inhaler, Journal of Aerosol Medicine and Pulmonary Drug Delivery, 27, 2, 2014. Crossref

  16. O'Callaghan Christopher, The delivery of proteins and peptides to the lung, Pediatric Pulmonology, 37, S26, 2004. Crossref

  17. Gibbons Aileen, McElvaney Noel G., Cryan Sally-Ann, A Dry Powder Formulation of Liposome-Encapsulated Recombinant Secretory Leukocyte Protease Inhibitor (rSLPI) for Inhalation: Preparation and Characterisation, AAPS PharmSciTech, 11, 3, 2010. Crossref

  18. Nguyen Juliane, Xie Xiulan, Neu Michael, Dumitrascu Rio, Reul Regina, Sitterberg Johannes, Bakowsky Udo, Schermuly Ralph, Fink Ludger, Schmehl Thomas, Gessler Tobias, Seeger Werner, Kissel Thomas, Effects of cell-penetrating peptides and pegylation on transfection efficiency of polyethylenimine in mouse lungs, The Journal of Gene Medicine, 10, 11, 2008. Crossref

  19. WOLFF R.K., Safety of Inhaled Proteins for Therapeutic Use, Journal of Aerosol Medicine, 11, 4, 1998. Crossref

  20. Frijlink H W, De Boer A H, Dry powder inhalers for pulmonary drug delivery, Expert Opinion on Drug Delivery, 1, 1, 2004. Crossref

  21. Kumar T. Mahesh, Misra Ambikanandan, Influence of absorption promoters on pulmonary insulin bioactivity, AAPS PharmSciTech, 4, 2, 2003. Crossref

  22. Packhaeuser Claudia B., Lahnstein Kerstin, Sitterberg Johannes, Schmehl Thomas, Gessler Tobias, Bakowsky Udo, Seeger Werner, Kissel Thomas, Stabilization of Aerosolizable Nano-carriers by Freeze-Drying, Pharmaceutical Research, 26, 1, 2009. Crossref

  23. Yu Jing-yu, Rosania Gus R., Cell-Based Multiscale Computational Modeling of Small Molecule Absorption and Retention in the Lungs, Pharmaceutical Research, 27, 3, 2010. Crossref

  24. Beck-Broichsitter Moritz, Schmehl Thomas, Seeger Werner, Gessler Tobias, Evaluating the Controlled Release Properties of Inhaled Nanoparticles Using Isolated, Perfused, and Ventilated Lung Models, Journal of Nanomaterials, 2011, 2011. Crossref

  25. Hertel Sebastian P., Winter Gerhard, Friess Wolfgang, Protein stability in pulmonary drug delivery via nebulization, Advanced Drug Delivery Reviews, 93, 2015. Crossref

  26. Shahiwala Aliasgar, Misra Ambikanandan, A preliminary pharmacokinetic study of liposomal leuprolide dry powder inhaler: A technical note, AAPS PharmSciTech, 6, 3, 2005. Crossref

  27. Schweizer Daniel, Serno Tim, Goepferich Achim, Controlled release of therapeutic antibody formats, European Journal of Pharmaceutics and Biopharmaceutics, 88, 2, 2014. Crossref

  28. Kayser Oliver, Kiderlen Albrecht F, Delivery strategies for antiparasitics, Expert Opinion on Investigational Drugs, 12, 2, 2003. Crossref

  29. Hertel Sebastian, Pohl Thomas, Friess Wolfgang, Winter Gerhard, Prediction of protein degradation during vibrating mesh nebulization via a high throughput screening method, European Journal of Pharmaceutics and Biopharmaceutics, 87, 2, 2014. Crossref

  30. Weers Jeffry G, Tarara Thomas E, Clark Andrew R, Design of fine particles for pulmonary drug delivery, Expert Opinion on Drug Delivery, 4, 3, 2007. Crossref

  31. Lizio Rosario, Damm Michael, Sarlikiotis Antonio W., Bauer Horst H., Lehr Claus-Michael, Low-temperature micronization of a peptide drug in fluid propellant: Case study cetrorelix, AAPS PharmSciTech, 2, 3, 2001. Crossref

  32. LIM Se-Hwan, PARK Hye Won, SHIN Chang-Hoon, KWON Jai-Hyun, KIM Chan-Wha, Human Insulin Microcrystals with Lactose Carriers for Pulmonary Delivery, Bioscience, Biotechnology, and Biochemistry, 73, 12, 2009. Crossref

  33. French Donna L., Edwards David A., Niven Ralph W., The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation, Journal of Aerosol Science, 27, 5, 1996. Crossref

  34. Bitonti Alan J., Dumont Jennifer A., Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway, Advanced Drug Delivery Reviews, 58, 9-10, 2006. Crossref

  35. Scheuch Gerhard, Kohlhaeufl Martin J., Brand Peter, Siekmeier Ruediger, Clinical perspectives on pulmonary systemic and macromolecular delivery, Advanced Drug Delivery Reviews, 58, 9-10, 2006. Crossref

  36. Jones Latarsha, Garcia-Contreras Lucila, Smyth Hugh, Garmise Robert, Hickey Anthony, Cooney Daniel, Medical and pharmaceutical aerosols, in Aerosols Handbook, 2004. Crossref

  37. Zijlstra Gerrit S., Hinrichs Wouter L.J., Boer Anne H. de, Frijlink Henderik W., The role of particle engineering in relation to formulation and de-agglomeration principle in the development of a dry powder formulation for inhalation of cetrorelix, European Journal of Pharmaceutical Sciences, 23, 2, 2004. Crossref

  38. Kusmartseva O., Kattige A.S., Price R., Smith P.R., In-line assessment of pulmonary drug delivery using light obscuration, Biosensors and Bioelectronics, 20, 3, 2004. Crossref

  39. Dailey Lea Ann, Wittmar Matthias, Kissel Thomas, The role of branched polyesters and their modifications in the development of modern drug delivery vehicles, Journal of Controlled Release, 101, 1-3, 2005. Crossref

  40. Choi Mina, Cho Minjung, Han Beom Seok, Hong Jin, Jeong Jayoung, Park Sangjin, Cho Myung-Haing, Kim Kwangmeyung, Cho Wan-Seob, Chitosan nanoparticles show rapid extrapulmonary tissue distribution and excretion with mild pulmonary inflammation to mice, Toxicology Letters, 199, 2, 2010. Crossref

  41. McMahon Graham T., Arky Ronald A., Inhaled Insulin for Diabetes Mellitus, New England Journal of Medicine, 356, 5, 2007. Crossref

  42. Patton John S., Mechanisms of macromolecule absorption by the lungs, Advanced Drug Delivery Reviews, 19, 1, 1996. Crossref

  43. Asgharian B., Price O.T., Hofmann W., Prediction of particle deposition in the human lung using realistic models of lung ventilation, Journal of Aerosol Science, 37, 10, 2006. Crossref

  44. Jyoti Kiran, Kaur Karanvir, Pandey Ravi Shankar, Jain Upendra Kumar, Chandra Ramesh, Madan Jitender, Inhalable nanostructured lipid particles of 9-bromo-noscapine, a tubulin-binding cytotoxic agent: In vitro and in vivo studies, Journal of Colloid and Interface Science, 445, 2015. Crossref

  45. Patton John S., Bukar Julie, Nagarajan Sudha, Inhaled insulin1Abbreviations: DM, diabetes mellitus; AIDs, acquired immune deficiency syndrome; SC, subcutaneous; DCCT, Diabetes Control and Complications Trial; IDDM, insulin-dependent diabetes mellitus; NIDDM, non-insulin-dependent diabetes mellitus; i.v., intravenous; DDPC, di-decanoyl-alpha-phosphatidylcholine; AUC, area under the curve; INH, inhaled; Cmax, maximum serum concentration; Cmin, minimum serum concentration; Tmax, time of maximum serum concentration; NS, not significant; HbA1c, hemoglobin A, Advanced Drug Delivery Reviews, 35, 2-3, 1999. Crossref

  46. Cho Wan-Seob, Cho Minjung, Kim Seoung Ryul, Choi Mina, Lee Jeong Yeon, Han Beom Seok, Park Sue Nie, Yu Mi Kyung, Jon Sangyong, Jeong Jayoung, Pulmonary toxicity and kinetic study of Cy5.5-conjugated superparamagnetic iron oxide nanoparticles by optical imaging, Toxicology and Applied Pharmacology, 239, 1, 2009. Crossref

  47. Hickey A.J., Durham P.G., Dharmadhikari A., Nardell E.A., Inhaled drug treatment for tuberculosis: Past progress and future prospects, Journal of Controlled Release, 240, 2016. Crossref

  48. Fängmark I., Carpin J.C., Stability of urease during aerosolization, Journal of Aerosol Science, 29, 3, 1998. Crossref

  49. Kunda Nitesh K., Alfagih Iman M., Saleem Imran Y., Hutcheon Gillian A., Polymer-based Delivery Systems for the Pulmonary Delivery of Biopharmaceuticals, in Pulmonary Drug Delivery, 2015. Crossref

  50. Reul Regina, Renette Thomas, Bege Nadja, Kissel Thomas, Nanoparticles for paclitaxel delivery: A comparative study of different types of dendritic polyesters and their degradation behavior, International Journal of Pharmaceutics, 407, 1-2, 2011. Crossref

  51. Pettit Dean K, Gombotz Wayne R, The development of site-specific drug-delivery systems for protein and peptide biopharmaceuticals, Trends in Biotechnology, 16, 8, 1998. Crossref

  52. Azarmi Shirzad, Roa Wilson H., Löbenberg Raimar, Targeted delivery of nanoparticles for the treatment of lung diseases, Advanced Drug Delivery Reviews, 60, 8, 2008. Crossref

  53. Dhanda Devender S., Kompella Uday B., Metered Dose Inhalers (MDIs) and Dry Powder Inhalers (DPIs) for Pulmonary Drug Delivery: CMC Issues, Clinical Research and Regulatory Affairs, 22, 1, 2005. Crossref

  54. Patel Neha, Craddock Bridget L, Staniforth John N, Tobyn Michael J, Welham Melanie J, Spray-dried insulin particles retain biological activity in rapid in-vitro assay, Journal of Pharmacy and Pharmacology, 53, 10, 2010. Crossref

  55. Mansour Heidi M., Rhee Yun-Seok, Park Chun-Woong, DeLuca Patrick P., LIPID NANOPARTICULATE DRUG DELIVERY AND NANOMEDICINE, in Lipids in Nanotechnology, 2012. Crossref

  56. Weers Jeffry G., Miller Danforth P., Formulation Design of Dry Powders for Inhalation, Journal of Pharmaceutical Sciences, 104, 10, 2015. Crossref

  57. Cázares-Delgadillo J., Ganem-Rondero A., Kalia Y.N., Human growth hormone: New delivery systems, alternative routes of administration, and their pharmacological relevance, European Journal of Pharmaceutics and Biopharmaceutics, 78, 2, 2011. Crossref

  58. Kuo Jung-hua Steven, Hwang Robin, Preparation of DNA dry powder for non-viral gene delivery by spray-freeze drying: effect of protective agents (polyethyleneimine and sugars) on the stability of DNA, Journal of Pharmacy and Pharmacology, 56, 1, 2010. Crossref

  59. Hoyer Herbert, Perera Glen, Bernkop-Schnürch Andreas, Noninvasive delivery systems for peptides and proteins in osteoporosis therapy: a retroperspective, Drug Development and Industrial Pharmacy, 36, 1, 2010. Crossref

  60. Gibbons Aileen M., McElvaney Noel G., Taggart Clifford C., Cryan Sally-Ann, Delivery of rSLPI in a liposomal carrier for inhalation provides protection against cathepsin L degradation, Journal of Microencapsulation, 26, 6, 2009. Crossref

  61. Mahesh Kumar T., Misra Ambikanandan, Formulation and Evaluation of Insulin Dry Powder for Inhalation, Drug Development and Industrial Pharmacy, 32, 6, 2006. Crossref

  62. Yu Jing-yu, Zheng Nan, Mane Gerta, Min Kyoung Ah, Hinestroza Juan P., Zhu Huaning, Stringer Kathleen A., Rosania Gus R., Mac Gabhann Feilim, A Cell-based Computational Modeling Approach for Developing Site-Directed Molecular Probes, PLoS Computational Biology, 8, 2, 2012. Crossref

  63. Misra Ambikanandan, Jinturkar Kaustubh, Patel Deepa, Lalani Jigar, Chougule Mahavir, Recent advances in liposomal dry powder formulations: preparation and evaluation, Expert Opinion on Drug Delivery, 6, 1, 2009. Crossref

  64. Friebel Christian, Steckel Hartwig, Single-use disposable dry powder inhalers for pulmonary drug delivery, Expert Opinion on Drug Delivery, 7, 12, 2010. Crossref

  65. Daugherty Ann L, Mrsny Randall J, Emerging technologies that overcome biological barriers for therapeutic protein delivery, Expert Opinion on Biological Therapy, 3, 7, 2003. Crossref

  66. Yhee Ji, Im Jintaek, Nho Richard, Advanced Therapeutic Strategies for Chronic Lung Disease Using Nanoparticle-Based Drug Delivery, Journal of Clinical Medicine, 5, 9, 2016. Crossref

  67. Stein Stephen W., Thiel Charles G., The History of Therapeutic Aerosols: A Chronological Review, Journal of Aerosol Medicine and Pulmonary Drug Delivery, 30, 1, 2017. Crossref

  68. Sanjar S., Matthews J., Treating Systemic Diseases via the Lung, Journal of Aerosol Medicine, 14, supplement 1, 2001. Crossref

  69. Francioso Antonio, Cossi Riccardo, Fanelli Sergio, Mastromarino Paola, Mosca Luciana, Studies on Trans-Resveratrol/Carboxymethylated (1,3/1,6)-β-d-Glucan Association for Aerosol Pharmaceutical Applications, International Journal of Molecular Sciences, 18, 5, 2017. Crossref

  70. Selim Assmaa O., Gouda Zienab A., Selim Sally A., An experimental study of a rat model of emphysema induced by cigarette smoke exposure and the effect of Survanta therapy, Annals of Anatomy - Anatomischer Anzeiger, 211, 2017. Crossref

  71. Lerondel S., Vecellio None L., Faure L., Sizaret P.-Y., Sene C., Pavirani A., Diot P., Le Pape A., Gene Therapy for Cystic Fibrosis with Aerosolized Adenovirus-CFTR: Characterization of the Aerosol and Scintigraphic Determination of Lung Deposition in Baboons, Journal of Aerosol Medicine, 14, 1, 2001. Crossref

  72. Edwards David A., Ben-Jebria Abdelaziz, Langer Robert, Recent advances in pulmonary drug delivery using large, porous inhaled particles, Journal of Applied Physiology, 85, 2, 1998. Crossref

  73. Nikolaou Maria, Krasia-Christoforou Theodora, Electrohydrodynamic methods for the development of pulmonary drug delivery systems, European Journal of Pharmaceutical Sciences, 113, 2018. Crossref

  74. Fischer Nicholas O., Weilhammer Dina R., Dunkle Alexis, Thomas Cynthia, Hwang Mona, Corzett Michele, Lychak Cheri, Mayer Wasima, Urbin Salustra, Collette Nicole, Chiun Chang Jiun, Loots Gabriela G., Rasley Amy, Blanchette Craig D., Ceña Valentin, Evaluation of Nanolipoprotein Particles (NLPs) as an In Vivo Delivery Platform, PLoS ONE, 9, 3, 2014. Crossref

  75. Nieto-Orellana Alejandro, Coghlan David, Rothery Malcolm, Falcone Franco H., Bosquillon Cynthia, Childerhouse Nick, Mantovani Giuseppe, Stolnik Snow, Dry-powder formulations of non-covalent protein complexes with linear or miktoarm copolymers for pulmonary delivery, International Journal of Pharmaceutics, 540, 1-2, 2018. Crossref

  76. Patton John, Breathing life into protein drugs, Nature Biotechnology, 16, 2, 1998. Crossref

  77. Bykova A. F., Ivanov I. M., Grebenyuk A. N., PROBLEMS AND PROSPECTS OF INHALATION APPLICATION OF PEPTIDE AND PROTEIN COMPOUNDS AS POTENTIAL MEDICAL RADIATION PROTECTIVE AGENTS, Medicо-Biological and Socio-Psychological Problems of Safety in Emergency Situations, 2, 2018. Crossref

  78. Nguyen Hiep X., Targeted Delivery of Surface-Modified Nanoparticles: Modulation of Inflammation for Acute Lung Injury, in Surface Modification of Nanoparticles for Targeted Drug Delivery, 2019. Crossref

  79. Xu Zhen, Hickey Anthony J., The Physics of Aerosol Droplet and Particle Generation from Inhalers, in Controlled Pulmonary Drug Delivery, 2011. Crossref

  80. Gibbons Aileen, Smyth Hugh D. C., Science and Technology of Nebulizers and Liquid-Based Aerosol Generators, in Controlled Pulmonary Drug Delivery, 2011. Crossref

  81. Beck-Broichsitter Moritz, Making Concentrated Antibody Formulations Accessible for Vibrating-Mesh Nebulization, Journal of Pharmaceutical Sciences, 108, 8, 2019. Crossref

  82. Ozcetin Aybike, Mutlu Samet, Bakowsky Udo, Archaebacterial Tetraetherlipid Liposomes, in Liposomes, 605, 2010. Crossref

  83. Häussermann S., Scheuch G., Siekmeier R., Targeting Drugs to the Lungs – The Example of Insulin, in Nanoparticles in medicine and environment, 2010. Crossref

  84. Yamamoto Akira, Ukai Hiroki, Morishita Masaki, Katsumi Hidemasa, Approaches to improve intestinal and transmucosal absorption of peptide and protein drugs, Pharmacology & Therapeutics, 211, 2020. Crossref

  85. Vinjamuri Bhavani Prasad, Kotha Arun K., Kolte Atul, Haware Rahul V., Chougule Mahavir B., Polymer Applications in Pulmonary Drug Delivery, in Applications of Polymers in Drug Delivery, 2021. Crossref

  86. Marante Tânia, Viegas Cláudia, Duarte Inês, Macedo Ana S., Fonte Pedro, An Overview on Spray-Drying of Protein-Loaded Polymeric Nanoparticles for Dry Powder Inhalation, Pharmaceutics, 12, 11, 2020. Crossref

  87. Canisius Sebastian, Hintergründe der Aerosolmedizin, Pneumo News, 13, 6, 2021. Crossref

  88. Ivanov I. M., Nikiforov A. S., Yudin M. A., Chepur S. V., Proshina Yu. A., Sventitskaya A. M., Prospects for Inhalation Delivery of Medical Protectors against Radiation Damage , Biology Bulletin, 47, 12, 2020. Crossref

  89. Elsabahy Mahmoud, Heo Gyu Seong, Lim Soon-Mi, Sun Guorong, Wooley Karen L., Polymeric Nanostructures for Imaging and Therapy, Chemical Reviews, 115, 19, 2015. Crossref

  90. Bruno Benjamin J, Miller Geoffrey D, Lim Carol S, Basics and recent advances in peptide and protein drug delivery, Therapeutic Delivery, 4, 11, 2013. Crossref

  91. Malhotra Hitesh, Kamboj Anjoo, Gautam Rupesh K., Medicinal Plant Based Advanced Drug Delivery System for the Treatment of Chronic Lung Diseases, in Medicinal Plants for Lung Diseases, 2021. Crossref

  92. Sodha Srushti J., Patel Manan, Nagarkar Rigved, Mohammed Irfan A., Patel Hiren, Translation of pulmonary protein therapy from bench to bedside: Addressing the bioavailability challenges, Journal of Drug Delivery Science and Technology, 64, 2021. Crossref

  93. Du Ju, Du Ping, Smyth Hugh DC, Hydrogels for controlled pulmonary delivery, Therapeutic Delivery, 4, 10, 2013. Crossref

  94. Edwards David A., Dunbar Craig, Bioengineering of Therapeutic Aerosols, Annual Review of Biomedical Engineering, 4, 1, 2002. Crossref

  95. Peek Laura J., Roberts Lydia, Berkland Cory, Poly(d,l-lactide-co-glycolide) Nanoparticle Agglomerates as Carriers in Dry Powder Aerosol Formulation of Proteins, Langmuir, 24, 17, 2008. Crossref

  96. Edwards David A., Hanes Justin, Caponetti Giovanni, Hrkach Jeffrey, Ben-Jebria Abdelaziz, Eskew Mary Lou, Mintzes Jeffrey, Deaver Daniel, Lotan Noah, Langer Robert, Large Porous Particles for Pulmonary Drug Delivery, Science, 276, 5320, 1997. Crossref

  97. Choi Won Seon, Murthy G. G. Krishna, Edwards David A., Langer Robert, Klibanov Alexander M., Inhalation delivery of proteins from ethanol suspensions, Proceedings of the National Academy of Sciences, 98, 20, 2001. Crossref

  98. Dong Zhengqi, Hamid Khuriah Abdul, Gao Yang, Lin Yulian, Katsumi Hidemasa, Sakane Toshiyasu, Yamamoto Akira, Polyamidoamine Dendrimers Can Improve the Pulmonary Absorption of Insulin and Calcitonin in Rats, Journal of Pharmaceutical Sciences, 100, 5, 2011. Crossref

  99. He Lin, Gao Yang, Lin Yulian, Katsumi Hidemasa, Fujita Takuya, Yamamoto Akira, Improvement of pulmonary absorption of insulin and other water-soluble compounds by polyamines in rats, Journal of Controlled Release, 122, 1, 2007. Crossref

  100. Antosova Zuzana, Mackova Martina, Kral Vladimir, Macek Tomas, Therapeutic application of peptides and proteins: parenteral forever?, Trends in Biotechnology, 27, 11, 2009. Crossref

  101. Pham Dinh-Duy, Fattal Elias, Tsapis Nicolas, Pulmonary drug delivery systems for tuberculosis treatment, International Journal of Pharmaceutics, 478, 2, 2015. Crossref

  102. KOLB MARTIN, MARGETTS PETER J., GALT TOM, SIME PATRICIA J., XING ZHOU, SCHMIDT MICHAEL, GAULDIE JACK, Transient Transgene Expression of Decorin in the Lung Reduces the Fibrotic Response to Bleomycin, American Journal of Respiratory and Critical Care Medicine, 163, 3, 2001. Crossref

  103. Charan Giri Nitai, Protein and Peptide Drug Delivery, in Smart Drug Delivery, 2022. Crossref

  104. Hickey Anthony James, Stewart Ian Edward, Inhaled antibodies: Quality and performance considerations, Human Vaccines & Immunotherapeutics, 18, 2, 2022. Crossref

  105. Hemetsberger Aybike, Preis Eduard, Engelhardt Konrad, Gutberlet Bernd, Runkel Frank, Bakowsky Udo, Highly Stable Liposomes Based on Tetraether Lipids as a Promising and Versatile Drug Delivery System, Materials, 15, 19, 2022. Crossref

Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen Preise und Aborichtlinien Begell House Kontakt Language English 中文 Русский Português German French Spain